The immunoSCAPE Story
immunoSCAPE was spun-out from the Agency of Science, Technology and Research (A*STAR) in Singapore. Dr Evan Newell, our co-founder, developed the core technology based on methods for specific T cell identification. We are committed to the continuous development of data analysis tools and immune profiling solutions to improve the robustness of our read-outs and the value we offer.
We launched in the spring of 2017 and have expanded our global reach with customers in the US, Europe, Africa, and Asia. immunoSCAPE Inc was launched in Cambridge, MA, US in 2018.
Who We Are
We are scientists – passionate in our pursuit of knowledge and discovery for the sake of the patients we ultimately serve.
- We demonstrate INTEGRITY in our conduct and our work.
- We continuously INNOVATE to solve problems and improve patient outcomes.
- We LISTEN to our partners and colleagues to improve the way we meet needs.
Board of Directors
formation, strategy, partnering, venture investment and licensing transactions. He is currently
providing advisory services to several early stage companies, venture capital enterprises and
academic centers. He was previously Vice President and Head of Strategic Academic Alliances
at Takeda Pharmaceuticals where he was responsible for establishing several broad drug
discovery alliances, including the Tri-Institutional Therapeutics Discovery Institute (Weill Cornell
Medicine, Rockefeller University and Memorial Sloan Kettering Cancer Center), the Alliance for
Innovative Medicines (Stanford University), the Seattle Partnership for Research in Innovative
Therapeutics (SPRInT, including the Fred Hutchinson Cancer Research Center, the University of
Washington, and Seattle Children’s Hospital), and the Dana Farber Cancer Institute. Before
leading Takeda’s SAA, he was VP at Takeda Ventures where he invested in several companies
including Envoy Therapeutics, later acquired by Takeda. Mr. Harrison has been working in the
biopharmaceutical industry since 1985 and has held senior positions in Alza Pharmaceuticals,
Connetics, PowderJect and XenoPort. He received a BS in Combined Science from Santa Clara
University with emphasis in Chemistry and Biochemistry.
Based in Ann Arbor, Michigan, John Freshley is a high-energy entrepreneur, company builder
and leader with 20+ years experience in a variety of healthcare-focused companies. He has
founded, launched, and/or led 8 early stage life science companies, including Compendia
Bioscience through its acquisition by Life Technologies (now Thermo Fisher).
Craig has a Ph.D. in Biochemistry with over 30 years of work experience managing the development of new product pipelines, intellectual property portfolios and has significant licensing as well as acquisition diligence experience. His expertise spans the technology disciplines of protein, cell and molecular biology for the Life Science Reagents, Drug Discovery and Biopharmaceutical Manufacturing markets. He has worked for both small privately held startups as well as large multinational publicly traded companies. He is currently running his own consulting business focusing on startups with novel technology.